Authors Benaam Niveshak
7 days
30 days
All time
Recent
Popular
Before discussing this company let us first understand the meaning and basic difference between some words which are often used interchangeably.
The need of such players arises as the R&D process to bring a product into market is expensive and time consuming.
On an average the R&D in pharma takes 14years with US$2.6Bn to bring a product to market with an overall success rate of ~4.1%
Even after investing substantial time and money, pharma companies are facing sustainability crisis due to dwindling ROI on R&D
Pharma companies invest around 15-20% of their revenues in R&D but in return the IIR < Cost of capital.
In 2020 it was expected to touch 0%
https://t.co/w1a9jNTpME
Syngene is a global CRAMS player providing end to end services in the entire value chain of forming a drug from a molecule.
It works with client around the world. Geography wise 76% revenue contribution is from US, followed by 12% from Europe.
The need of such players arises as the R&D process to bring a product into market is expensive and time consuming.
On an average the R&D in pharma takes 14years with US$2.6Bn to bring a product to market with an overall success rate of ~4.1%
Even after investing substantial time and money, pharma companies are facing sustainability crisis due to dwindling ROI on R&D
Pharma companies invest around 15-20% of their revenues in R&D but in return the IIR < Cost of capital.
In 2020 it was expected to touch 0%
https://t.co/w1a9jNTpME
Syngene is a global CRAMS player providing end to end services in the entire value chain of forming a drug from a molecule.
It works with client around the world. Geography wise 76% revenue contribution is from US, followed by 12% from Europe.